Combining Two Obesity Drugs Hits Five Hormone Receptors and Drives Unprecedented Weight Loss in Rats

A new preclinical study suggests that the next leap in obesity medicine may not come from a single blockbuster molecule, but from deliberately stacking two of them. In research published in Nature Metabolism, a team at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen reports that combining cagrilintide, a long-acting amylin receptor co-agonist, with retatrutide, a triple agonist of the GLP-1, GIP and glucagon receptors, produces weight loss in obese rats that exceeds anything achieved by either drug alone or by existing comparator combinations. The work, led by Jonas Petersen and Christoffer Merrild as co-first authors under senior author Christoffer Clemmensen, offers a detailed pharmacological and molecular rationale for what the investigators call five-receptor polypharmacology, a strategy that simultaneously engages the incretin axis and the amylin system to reshape energy balance.

The rationale for the experiment rests on how differently the two drug classes act. Incretin-based therapies such as semaglutide and tirzepatide mimic gut-derived hormones that slow gastric emptying, enhance insulin secretion and signal to brainstem and hypothalamic circuits that suppress appetite. Amylin-based agents such as cagrilintide act on a distinct receptor complex, the amylin receptor formed by AM-LNR in combination with the calcitonin receptor CALCR, and appear to reduce food intake through partly separable neural pathways. Retatrutide, the most advanced triple agonist in clinical development, adds glucagon receptor activity, which in preclinical models is associated with increased energy expenditure and favorable effects on lipid metabolism. The Copenhagen group reasoned that engaging all five receptors at once might capture complementary benefits that no single molecule, however sophisticated, could deliver.

To test this, the researchers used diet-induced obese male rats, a standard preclinical model in which animals become obese after prolonged exposure to a high-fat diet. Animals received daily subcutaneous injections of cagrilintide, retatrutide, the two drugs co-administered, or comparator regimens built around semaglutide and tirzepatide at matched doses. The results were striking: co-administration of cagrilintide and retatrutide produced dose-dependent reductions in body weight and food intake that surpassed both equimolar monotherapies and matched-dose combinations incorporating the established incretin drugs. Across multiple studies, the combination also reduced fat-pad masses and improved circulating markers of metabolic health, including total cholesterol, triglycerides and insulin, without evidence of the liver enzyme elevations that can signal hepatic stress.

A central question in obesity pharmacology is whether a drug simply makes animals eat less or whether it does something more. The team addressed this with pair-feeding and weight-matching experiments, designs in which control animals are given either the same amount of food as treated animals or are calorie-restricted until their body weight matches that of drug-treated animals. These experiments revealed that the enhanced weight loss seen with the combination could not be explained by reduced food intake alone. In other words, even when caloric intake was held constant, the cagrilintide-retatrutide pairing drove greater reductions in body weight than calorie restriction by itself, pointing to additional mechanisms, potentially involving energy expenditure, nutrient partitioning or the glucagon receptor’s effects on lipid handling.

The study went beyond physiology into molecular territory. Using advanced mass spectrometry workflows, including enrichment of extracellular vesicles from plasma, the researchers profiled the circulating proteome of treated animals. Plasma proteomic analysis showed that the combination therapy was associated with enrichment of proteins involved in bioenergetic processes, a signature consistent with altered fuel metabolism rather than mere caloric deprivation. By comparing drug-treated animals with weight-matched calorie-restricted controls, the team could separate molecular changes that simply track weight loss from those that are drug-specific, an analytical distinction they argue is essential for interpreting the biology of next-generation anti-obesity therapies.

The brain was the other major focus. Obesity drugs act centrally, and the specific neuronal programs they engage determine both their efficacy and their side-effect profile. The researchers performed bulk RNA sequencing of two key brain regions: the hypothalamus, the master hub of energy homeostasis, and the dorsal vagal complex in the brainstem, a critical relay for visceral sensory information and a major site of action for GLP-1-based drugs. Brain transcriptomic profiling revealed convergent central neuronal programs linked to energy balance regulation, and importantly, the combination therapy elicited stronger responses in hypothalamic and dorsal vagal complex gene modules than either monotherapy. The team used co-expression network analysis and cell-type enrichment mapping to connect these transcriptional signatures to specific neuronal populations, and found that modules activated by the combination were enriched for genes previously associated with human body mass index in genome-wide association studies.

These molecular findings carry practical implications for drug design. The field is currently racing to develop unimolecular multi-receptor agonists, single peptides engineered to bind several receptors at once, exemplified by retatrutide itself and by amycretin, a GLP-1 and amylin receptor co-agonist that has shown promising results in early clinical trials. The Copenhagen study suggests a blueprint for such molecules: a next-generation single agent that combines GLP-1, GIP, glucagon and amylin receptor activity in one backbone could, in principle, reproduce the pharmacology of the cagrilintide-retatrutide pair without requiring two separate injections. The authors frame their preclinical data as direct guidance for the design of these next-generation unimolecular agonists, identifying which receptor combinations and dose ratios appear most productive.

The clinical context makes the findings timely. Retatrutide has delivered powerful weight loss in a pivotal phase 3 obesity trial, and co-administered cagrilintide and semaglutide, marketed as a fixed-dose combination, has already demonstrated substantial efficacy in adults with overweight or obesity. Yet a persistent challenge remains in achieving maximal weight loss and metabolic control, particularly for patients living with both obesity and type 2 diabetes. The Copenhagen study suggests that adding amylin receptor agonism on top of a triple incretin agonist may push efficacy further than simply optimizing incretin pharmacology alone. The researchers also probed tolerability signals, including conditioned taste aversion tests in lean rats, which are used as a proxy for nausea-like aversive effects, and found dose-dependent responses that will inform how such combinations might be titrated in future studies.

Important caveats apply. All of the efficacy data come from male rats, and sex differences in response to obesity pharmacotherapy are well documented, so replication in female animals and eventually in humans will be essential. The doses used in rodents also cannot be translated directly to the clinic, and combination therapy raises questions about tolerability, cost and dosing complexity that only human trials can resolve. Nonetheless, the study provides one of the most comprehensive preclinical characterizations to date of what happens when the incretin and amylin systems are engaged simultaneously, integrating behavioral, metabolic, proteomic and transcriptomic readouts within a single experimental framework. The underlying data, including proteomic datasets deposited in the PRIDE repository and gene expression data in ArrayExpress, along with all analysis code released on GitHub, have been made openly available to the research community.

As obesity medicines evolve from single-hormone mimics toward rationally designed polypharmacology, the Copenhagen results make a compelling case that the amylin system is the most promising partner for the incretin drugs that have already transformed the field. If the five-receptor strategy translates from rats to humans, the ceiling on pharmacologically achievable weight loss, long constrained by the limits of GLP-1 receptor agonism, may be considerably higher than anyone dared to project just a few years ago.

Subject of Research: Combination therapy with cagrilintide and retatrutide for enhanced weight loss and metabolic outcomes in obese rats

Article Title: Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats

Article References: Petersen, J., Merrild, C., Holm, S. K., Kurgan, N., Hassan, S., Mathiesen, C. V., Börchers, S., Svendsen, C., D’Anna, S., Andersen, N. R., Klein, A. B., Fritzen, A. M., Deshmukh, A. S., Pers, T. H., & Clemmensen, C. (2026). Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism. https://doi.org/10.1038/s42255-026-01603-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01603-y

Keywords: cagrilintide, retatrutide, obesity, GLP-1 receptor agonist, amylin, glucagon receptor, GIP, weight loss pharmacotherapy, Nature Metabolism, multi-receptor agonist, metabolic health, preclinical study